Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EarLy extra Measles immunisation during a measles Outbreak (ELMO)
2024-513395-18-00Phase 4Authorised
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Measles-specific virus neutralising antibody concentrations 4 weeks post MMR-0 immunisation. Planned start Jul 2024; status: authorised.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2024-513395-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513395-18-00.